New York

Bristol-Myers Squibb, BioLabs Announce Founding Sponsorship in Support of Promising Biotech Companies in New York

Wednesday, November 01, 2017

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and BioLabs, a network of shared lab facilities for high-potential life-science startups, located in the nation’s key biotech innovation clusters, today announced Bristol-Myers Squibb as the Founding Sponsor of BioLabs’ newest location, BioLabs@NYULangone. This BioLabs site was launched in partnership with NYU Langone Health. As part of the agreement, for each year of active sponsorship, Bristol-Myers Squibb can nominate up to three innovative life-sciences and biotech startup companies per year to take up residence in BioLabs’ facilities at 180 Varick Street in Manhattan. The nomination process will launch in early 2018.

“We are thrilled to have Bristol-Myers Squibb as Founding Sponsor in New York, and excited to have them as part of BioLabs’ growing roster of sponsors,” said BioLabs CEO Johannes Fruehauf, M.D., Ph.D. “Clearly, there is a huge pent-up need for our model in The City; our sponsors are helping make BioLabs@NYULangone the best place to start a science-based startup in New York.”

Commenting on the Golden Ticket nomination program, he continued, “At LabCentral in Cambridge, where Bristol-Myers Squibb Company is a Platinum Sponsor, BMS Golden Ticket winners to date were first-time CEOs, fresh out of academia working to move early-stage science from the lab bench toward clinical trials. They speak regularly of the valuable insights they have gained from interactions with Bristol-Myers Squibb.”

“Bristol-Myers Squibb is excited to sponsor BioLabs New York, which serves as a launchpad for scientific innovation,” said Carl Decicco, Senior Vice President and Head of Discovery at Bristol-Myers Squibb. “The BioLabs model enables companies to advance research in a collaborative environment, which is aligned with our focus on accelerating discovery and development of transformational medicines for patients with serious diseases. We’re looking forward to learning about these emerging companies that will take up residence in the BioLabs@NYULangone.”

“Our companies will hit the ground running as part of the largest fully managed biotech co-working space in Manhattan,” said Nicole McKnight Ph.D., managing director of BioLabs New York. “It’s a pleasure to work with the Bristol-Myers Squibb team to bring this project to fruition.”

A Golden Ticket represents one underwritten bench space per year for one scientist at BioLabs, and a priority spot on the waiting list. The Golden Ticket also promotes collaboration among sponsors and the start-up companies; the program provides sponsors with early access to potentially transformational targets and technology, and the start-ups with the mentorship of their sponsor teams.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at or follow us on LinkedIn, Twitter, YouTube and Facebook.

About BioLabs and BioLabs New York ( twitter: @BioLabsHQ @BioLabsNY

BioLabs is a membership-based network of shared lab facilities located in the nation’s key biotech innovation clusters, designed exclusively for high-potential, early-stage life science companies. It offers coworking environments that pair premium, fully equipped and supported lab and office space with unparalleled access to capital and industry partners. This fertile, supportive ecosystem allows nascent companies to shift their focus from startup operations to innovation so they can reach their scientific potential quickly and achieve business success. Companies can start with a single bench, and scale up as they grow. BioLabs’ founding site is in Kendall Square, Cambridge, Massachusetts, with additional locations in North Carolina; San Diego, California; and opening in New York City, BioLabs@NYULangone. Partner sites include LabCentral in Kendall Square, and QB3@953 in San Francisco, California.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2016 in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.